Agilent Technologies, a global leader in scientific products and services, has witnessed a surge in its stock price, driving valuations to unprecedented levels.
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide
Agilent’s revenue has decreased by (9% )to $1.68bn in Q4FY23 from $1.84bn in Q4FY22, COGS as % of sales has increased to 46% in Q4FY23 from 45% in Q4FY22 and on a yearly basis it has increased to 49.1% in FY23 from 45.6% in FY22.
Over the last 3 months Agilent Technologies stock has generated return of 24.53%, the price of stock has increased to $130.10 on 31st Jan 2024 from $104.47 on 2nd Nov 2023.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
$288.00
Scan this QR code using your UPI app.
Amount: ₹499
malay.ia@validhdfc
After payment, email your transaction ID or payment confirmation to [email protected] , along with your name and email address. We'll verify your payment and email the report.
STMicroelectronics N.V. Q3FY26 - ST is expanding its supply of optical transceivers and power chips to cloud datacenter builders.
$240.00
Meta Platforms, Inc (Q3FY26) - Meta delivered Q3FY26 revenue of $64.6bn, up 26% YoY, with ad revenue of $63.1bn also up 26% on a constant currency basis.
$240.00
General Dynamics Corporation Q3FY26 - During 9MFY26, the aerospace and defense sector delivered high single digit top line growth YoY, supported by steady European defense rearmament and solid demand for commercial airframes.
$240.00
Twist Bioscience Corporation (Q3FY26) - Twist’s revenue expansion is primarily driven by volume gains across its Next-Generation Sequencing (NGS) target enrichment panels and synthetic biology tools.
$224.00
$170.00
Capital Deployment - 2026 highlights key themes including the move away from physical assets and bank deposits towards equity and alternative investments, the democratization of high-yield asset classes through technology, and the surge in retail participation driven by mobile-first platforms and open banking infrastructure.
$225.00
A new Samvat brings fresh opportunities, and new questions for investors. As market conditions shift and valuations reset, which stocks deserve a place on your watchlist? Discover 10 research-backed stock ideas for Samvat 2083, selected through CrispIdea’s multi-factor scoring model and analysed for earnings potential, business fundamentals and valuation.
₹499.00
The Consumerization of Healthcare - 2026: Gen Z and younger Millennials are fundamentally rewriting the rules of healthcare. Instead of relying on a primary care physician as the first point of contact, their healthcare journey now begins with a TikTok video, a Reddit thread, or a conversation with an AI chatbot.
$850.00